贝卡林标蛋白,Annexin A2,是新的抗瘤药物的标
Yoshio Kusakabe1, Kazuya Matsumoto1, Takahiro Tsuyuki1
1Faculty of Pharma-Sciences, Teikyo University, Tokyo, Japan.
Scientific reports
|September 18, 2024
概括
贝卡林是一种来自Scutellaria baicalensis的化合物,通过准Annexin A2.2,显示出抗瘤作用. 抑制Annexin A2可能导致新的癌症药物开发.
科学领域:
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 贝卡林是一种来自Scutellaria baicalensis Georgi的黄类化合物,具有抗瘤和诱导亡的特性.
- 其精确的药理机制,特别是其分子点,需要进一步阐明药物开发.
- 参与等离子体激活器系统的蛋白质Annexin A2被确定为baicalin的关键标.
研究的目的:
- 为了研究的抗瘤和诱导亡的分子机制.
- 确认这些效应是否通过其与附件A2的相互作用来介导.
- 探索Annexin A2作为新型抗癌药物的治疗点的潜力.
主要方法:
- 使用生化分离技术识别贝卡林的标蛋白.
- 产生Annexin A2敲击HepG2细胞以研究baicalin的影响.
- 定量实时PCR (RT-qPCR) 用于评估mRNA表达水平.
- 卡斯帕-3活性测定用于测量亡诱导.
主要成果:
- 附件A2被成功确定为贝卡林的标蛋白.
- 附录素A2,与S100A10复合,激活组织等离子体激活剂 (tPA),促进与癌症相关的基因表达 (STAT-3,NF-κB).
- 在HepG2细胞中对Annexin A2的抑制表明,baicalin的抗瘤和诱导亡的作用确实是由Annexin A2调解的.
结论:
- 拜卡林通过与Annexin A2的相互作用来发挥其抗瘤和诱导亡的作用.
- 素A2-S100A10-tPA通路在调解贝卡林抗癌活性方面发挥着至关重要的作用.
- 向Annexin A2为开发抗癌新型治疗剂提供了一个有前途的战略.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Targets for Drug Action: Overview
6.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.1K
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K


